

ASX Announcement

17 April 2025

Cleansing notice under section 708A(5)(e) of the Corporations Act

This notice is being given by Recce Pharmaceuticals Ltd (**ASX:RCE**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company today issued 17,857,143 fully paid ordinary shares (**New Shares**) in accordance with the Company's ASX announcement on 10 April 2025 regarding the placement raising A\$5.0 million (before costs) and as detailed in the Appendix 2A. For the purposes of section 708A(6) of the Corporations Act, the Company advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, the information that is 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act concerns additional clinical trials for which the Company is in the process of obtaining approvals.

This announcement has been approved for release by the Board.

For more information, please contact:

Maggie Niewidok

Company Secretary

E: company.secretary@recce.com.au



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 T +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA